Results for tag: "Oral Hypoglyceimic Agent"

The Oral Hypoglycemic Agent market is a segment of the Endocrine and Metabolic Disorders Drugs market. These drugs are used to treat diabetes, a condition in which the body does not produce enough insulin or is unable to use the insulin it produces. Oral Hypoglycemic Agents are used to help regulate blood sugar levels in people with diabetes. They work by stimulating the pancreas to produce more insulin or by increasing the body's sensitivity to insulin. Commonly prescribed Oral Hypoglycemic Agents include sulfonylureas, meglitinides, biguanides, and thiazolidinediones. Some companies in the Oral Hypoglycemic Agent market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and Boehringer Ingelheim. Show Less Read more